Psoriasis

The AJMC® Psoriasis compendium is a comprehensive resource for clinical news and expert insights for the chronic skin disease, which tends to go through cycles where it flares and goes into remission.

Latest News

Pediatric Psoriasis | Image Credit: Evgeniya Primavera - stock.adobe.com .jpeg
Review Reveals the Hidden Burden of Psoriasis on Children, Families

September 15th 2025

A new study highlights the epidemiological, humanistic, and economic impact of pediatric psoriasis, with findings showing greater challenges in moderate to severe cases.

Person reading on phone | Image credit: Farknot Architect - stock.adobe.com
Opportunities, Challenges in Digital Media and Psoriasis

September 10th 2025

Doctor examines patient with psoriasis rash | ARTFULLY-79 - stock.adobe.com
Real-World Data Show 12-Month Drug Survival Rates Among Anti-TNF Biosimilars in Psoriasis, PsA

September 8th 2025

Adalimumab | Image credit: luchschenF - stock.adobe.com
Infection Risk Higher in HS Compared With Psoriasis With Adalimumab

September 2nd 2025

Psoriatic arthritis | Image credit: Oporty786 - stock.adobe.com
The Totality of Evidence of Ustekinumab Biosimilar SB17

September 1st 2025

A Personalized Approach to Disease Management in Psoriasis

A panel of experts discuss their personalized approaches to treating patients with psoriasis and comorbidities such as metabolic syndrome.

Ryan Haumschild, PharmD, MS, MBA, Bhavesh Shah, PharmD, Mark Lebwohl, MD, and Robert Groves, MD.
Continuing Medical Education
View All
September 16th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
September 16th 2025

Innovations in Hidradenitis Suppurativa Treatment: Navigating the Evolving Landscape for Managed Care Professionals

August 19, 2025 | 1:00 PM & 8:00 PM ET
September 16th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Study Links Severity of Psoriasis, Nonalcoholic Fatty Liver Disease
October 10th 2019

Study Links Severity of Psoriasis, Nonalcoholic Fatty Liver Disease

Mary Caffrey
Previous work has linked psoriasis and nonalcoholic fatty liver disease, but this is one of the first studies to tie together the severity of the 2 conditions.
Dr Steven R. Feldman on Managing Psoriasis in Patients With Metabolic Syndrome
October 5th 2019

Dr Steven R. Feldman on Managing Psoriasis in Patients With Metabolic Syndrome

Steven R. Feldman, MD, PhD, professor of dermatology, Wake Forest School of Medicine, discusses the challenges clinicians face when managing psoriasis in patients who also have metabolic syndrome.
PASI Scores Can Indicate Who Will, Will Not Respond to Tildrakizumab for Psoriasis, Study Says
October 1st 2019

PASI Scores Can Indicate Who Will, Will Not Respond to Tildrakizumab for Psoriasis, Study Says

AJMC Staff
Knowing who may respond to tildrakizumab early on may help providers and patients decide whether to continue with treatment, the researchers said.
Site Logo
September 27th 2019

Poster Recap: Associations Among Opioid Use, Outpatient Visits, and Comorbidities in Patients With Moderate-to-Severe Psoriasis

Zhdanava M, Teeple A, Pilon D, Shak N, Fitzgerald T, Lefebvre P. Opioid healthcare resource use among privately insured moderate-to-severe psoriasis patients in the US. Poster presented at: ISPOR 2019 May 18-22, 2019 New Orleans, LA. ispor.org/heor-resources/presentations-database/presentation/intl2019-2217/92246.
Site Logo
September 27th 2019

Poster Recap: Comorbidities, Infections, and Treatments of Patients With Psoriasis

Peyerl FW, Varsos GV, Shen M, et al. Comorbidities, infections treatment patterns in psoriasis patients: a retrospective analysis of a large US electronic health record database. Poster presented at: ISPOR 2019 May 18-22, 2019 New Orleans, LA. ispor.org/heor-resources/presentations-database/presentation/intl2019-2217/91304.
Site Logo
September 27th 2019

Poster Recap: Biologics and Apremilast Adherence Patterns of Patients With Moderate to Severe Plaque Psoriasis Grouped by Metabolic Syndrome Status

Feldman SR, Zhang J, Martinez D, et al. Treatment patterns of biologics apremilast among patients with moderate to severe plaque psoriasis by metabolic syndrome status. Poster presented at: ISPOR 2019 May 18-22, 2019 New Orleans, LA. ispor.org/heor-resources/presentations-database/presentation/intl2019-1479/92502.
Site Logo
September 27th 2019

Poster Recap: Adherence Rates and Additional Treatment Patterns With Biologics and Apremilast for Moderate-to-Severe Plaque Psoriasis

Feldman SR, Zhang J, Zhao Y, et al. Apremilast treatment patterns in moderate-to-severe plaque psoriasis. Poster presented at: AMCP Managed Care & Specialty Pharmacy Annual Meeting March 25-28, 2019 San Diego, CA.
No Association Between Biologics to Treat Psoriasis and Psychiatric Illness
September 26th 2019

No Association Between Biologics to Treat Psoriasis and Psychiatric Illness

Laura Joszt, MA
Patients with psoriasis who were treated with biologics were less likely to develop psychiatric illnesses compared with patients not treated with biologics; however, the researchers did note treatment selection may have influenced the findings.
Early Levels of Ustekinumab May Predict Longer-term Response in Patients With Psoriasis
September 21st 2019

Early Levels of Ustekinumab May Predict Longer-term Response in Patients With Psoriasis

Laura Joszt, MA
Measurement of drug levels early in treatment with ustekinumab for patients with psoriasis may be able to successfully predict patient response and, therefore, direct a treatment strategy.
Researchers Examine Metabolic Syndrome Links to Inflammatory Skin Disorder Lichen Planus
September 20th 2019

Researchers Examine Metabolic Syndrome Links to Inflammatory Skin Disorder Lichen Planus

AJMC Staff
Psoriasis is known to be linked with metabolic syndrome, which is triggered by chronic inflammation and fosters obesity and dyslipidemia. A recent study looked at another chronic inflammatory skin disease, lichen planus, to better understand any associations with metabolic syndrome.
Case Report Describes Patient With Psoriasis Who Developed IBD After Secukinumab
September 11th 2019

Case Report Describes Patient With Psoriasis Who Developed IBD After Secukinumab

Allison Inserro
The discussion about whether existing inflammatory bowel disease (IBD) or new IBD can worsen after secukinumab therapy is not resolved, the researchers said.
Could Understanding HLA-C Lead to Precision Therapy in Psoriatic Arthritis?
September 9th 2019

Could Understanding HLA-C Lead to Precision Therapy in Psoriatic Arthritis?

Kelly Davio
Human leukocyte antigen c (HLA‐C), a protein encoded by the HLA-C gene, plays an important role in protecting against both cancer and viruses. At the same time, it has been implicated in autoimmune diseases, including rheumatic diseases, though the mechanism by which it contributes to the pathogenesis of these diseases is not yet clear.
More Research Needed About Link Between Psoriasis, Alcohol
September 5th 2019

More Research Needed About Link Between Psoriasis, Alcohol

Allison Inserro
Some patients may use alcohol to cope with the psychological and social aspect of psoriatic disease, but using alcohol may be associated with worse adherence to treatment.
Screen Patients With Psoriasis for Obstructive Sleep Apnea, Researchers Say
September 3rd 2019

Screen Patients With Psoriasis for Obstructive Sleep Apnea, Researchers Say

AJMC Staff
Patients with psoriasis should be opportunistically screened for obstructive sleep apnea, an independent risk factor for cardiovascular disease, said the authors of a recent study.
5 Things About Psoriasis and Its Complications
August 30th 2019

5 Things About Psoriasis and Its Complications

Allison Inserro
August is National Psoriasis Month, which aims to raise awareness about this chronic autoimmune disease affecting more than 8 million Americans. Here are 5 things to know about psoriasis and its complications.
Psoriasis Patient Group Seeks to Curb Step Therapy Use With State Legislation
August 30th 2019

Psoriasis Patient Group Seeks to Curb Step Therapy Use With State Legislation

Allison Inserro
The National Psoriasis Foundation is working to get laws to curb to step therapy practices at the state level.
Celgene Sells Psoriasis Drug Otezla to Amgen for $13.4 Billion
August 26th 2019

Celgene Sells Psoriasis Drug Otezla to Amgen for $13.4 Billion

Allison Inserro
The price for Otezla is higher than many analysts expected.
US Patients With Psoriasis Face 2-Fold Mortality Risk, Study Finds
August 22nd 2019

US Patients With Psoriasis Face 2-Fold Mortality Risk, Study Finds

Mary Caffrey
Findings appeared this month in the Journal of the American Academy of Dermatology.
Treating RA With Anti-TNF Agents Is Linked With a Higher Risk of Incident Psoriasis
August 19th 2019

Treating RA With Anti-TNF Agents Is Linked With a Higher Risk of Incident Psoriasis

Kelly Davio
Biologics have become the standard of care for rheumatoid arthritis (RA) that fails to respond adequately to conventional disease-modifying antirheumatic agents (DMARDs), and overall, these agents are safe and effective. However, an association between treatment with anti–tumor necrosis factor (anti-TNF) agents and new-onset psoriasis in patients with RA has been observed.
Researcher Excited About Future of Psoriasis Treatment
August 16th 2019

Researcher Excited About Future of Psoriasis Treatment

Allison Inserro
A psoriasis researcher discusses a new class of psoriasis treatments.
Obesity, Insulin Resistance Are Linked With Advanced Liver Fibrosis in Patients With Psoriasis
August 12th 2019

Obesity, Insulin Resistance Are Linked With Advanced Liver Fibrosis in Patients With Psoriasis

Kelly Davio
“Our data suggest that people with central obesity, insulin resistance, and active psoriasis are the most at risk for liver fibrosis,” wrote the authors, and “if use of methotrexate is a risk factor, it is not the only risk factor and for most patients it is unlikely to be the most important risk factor.”
Subclinical Atherosclerosis Seen in Patients With Psoriatic Arthritis
August 9th 2019

Subclinical Atherosclerosis Seen in Patients With Psoriatic Arthritis

AJMC Staff
A recent review of biomarkers of subclinical atherosclerosis in patients with psoriatic arthritis (PsA) showed more severe atherosclerotic disease compared with patients who have only psoriasis.
Systematic Review Finds No Increased Risk to Fetus After Parental Exposure to Biologics for Psoriasis
August 5th 2019

Systematic Review Finds No Increased Risk to Fetus After Parental Exposure to Biologics for Psoriasis

During a recent meeting of the British Association of Dermatologists, a team of researchers from the United Kingdom reported on a systematic review of literature on adults exposed to biologics during conception and/or pregnancy, and they report that they did not find increased risk to the fetus following maternal or paternal biologic exposure.
Biologic Therapy for Psoriasis Reduced Coronary Inflammation, Study Says
July 31st 2019

Biologic Therapy for Psoriasis Reduced Coronary Inflammation, Study Says

Allison Inserro
Biologic treatment for moderate to severe psoriasis was linked with reduced coronary inflammation as determined by a new imaging biomarker, according to a study published in JAMA Cardiology.
Meta-Analysis Shows Patients With Psoriasis at Significantly Elevated Risk for Cancer
July 29th 2019

Meta-Analysis Shows Patients With Psoriasis at Significantly Elevated Risk for Cancer

Kelly Davio
In a study presented at the British Association of Dermatologists’ 99th Annual Meeting in Liverpool, United Kingdom, July 2-4, 2019, researchers from the University of Manchester and the Salford Royal National Health Service Foundation Trust reported on an effort to assess evidence on the risk of cancer in patients with psoriasis. They found that there are a number of site-specific cancers for which patients with psoriasis are at elevated risk.
Therapeutic Drug Monitoring Can Help With Clinical Decision Making in Psoriasis, Study Says
July 27th 2019

Therapeutic Drug Monitoring Can Help With Clinical Decision Making in Psoriasis, Study Says

AJMC Staff
Therapeutic drug monitoring that includes the measurement of trough concentrations and anti-drug antibodies, along with clinical response, is a tool for clinical decision making.
Biologic Treatment Is Associated With Better Bone Health in Patients With Psoriatic Arthritis
July 23rd 2019

Biologic Treatment Is Associated With Better Bone Health in Patients With Psoriatic Arthritis

Kelly Davio
Given that psoriatic arthritis is associated with increased fracture risk, neutralizing the key proinflammatory and bone-destructive mediators of the disease, wrote the authors, appears to be important to restoring bone health.
Obesity More Common in Those With Psoriasis Alone Compared With Those With Wider Disease
July 19th 2019

Obesity More Common in Those With Psoriasis Alone Compared With Those With Wider Disease

AJMC Staff
While obesity is frequently observed in patients with psoriatic disease, it is even more common in those who have only psoriasis alone, researchers said.
Treating Psoriasis With Biologics May Have Cardiac Benefits
July 15th 2019

Treating Psoriasis With Biologics May Have Cardiac Benefits

Kelly Davio
The use of biologics to treat psoriasis has increased over time, and a recent study has demonstrated that these drugs may have benefits that extend well beyond clearing patients’ skin. The study, published in Cardiovascular Research, found that biologic therapy for psoriasis was associated with a reduction in coronary artery disease.
Survey: Why Patients With Psoriasis Turn to Complementary and Alternative Medicines
July 13th 2019

Survey: Why Patients With Psoriasis Turn to Complementary and Alternative Medicines

Allison Inserro
Patients with psoriasis frequently use complementary and alternative medicines to treat their symptoms.
<1
...
10111213141516>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo